Bristol-Myers Squibb Co - Company Profile
Powered by 
All the sales intelligence you need on Bristol-Myers Squibb Co in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bristol-Myers Squibb Co fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bristol-Myers Squibb Co.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreBristol-Myers Squibb Co (BMS) is a biopharmaceutical company. It discovers, develops, licenses, manufactures, markets, distributes, and commercializes biopharmaceutical products. The company offers its products in therapy areas such as oncology, hematology, immunology, cardiovascular, and neuroscience. It also engages in co-development, co-commercialization, licensing, or joint venture arrangements with third parties to develop specific drugs. BMS distributes its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies through brands such as Opdivo, Reblozyl, Krazati, Sprycel, and Sotyktu, among others. It operates manufacturing units in the US, Switzerland, Puerto Rico, Ireland, and the Netherlands. BMS is headquartered in Princeton, New Jersey, the US.
Headquarters
United States of America
Address
Route 206 and Province Line Road, Princeton, New Jersey, 08543
Website
www.bms.com
Telephone
1 609 2524621
No of Employees
32,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BMY (NYSE)
Revenue (2024)
$48.2B
-0.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
178.8%
(2024 vs 2023)
Market Cap*
$115.3B
Net Profit Margin (2024)
XYZ
179.0%
(2024 vs 2023)
* As of and is in US$
Bristol-Myers Squibb Co premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Opdivo (nivolumab) | Opdivo |
| Qvantig (nivolumab and hyaluronidase-nvhy) | Qvantig |
| Orencia (abatacept) | Orencia |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company signed a partnership with Mariska Hargitay to introduce Investigating Myeloma, a multiple myeloma awareness campaign. |
| 2026 | Regulatory Approval | In June, the company secured approval from the European Commission for Opdivo (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and adolescent patients 12 years of age and older with previously untreated Stage III or IV classical Hodgkin Lymphoma. |
| 2026 | Asset Disposal | In April, the company sold its drug manufacturing facility located in Phoenix, Arizona, the US, to ROIS Phoenix Inc. |
Competitor Comparison
| Key Parameters | Bristol-Myers Squibb Co | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Switzerland |
| City | Princeton | New Brunswick | Indianapolis | Rahway | Basel |
| State/Province | New Jersey | New Jersey | Indiana | New Jersey | Basel-Stadt |
| No. of Employees | 32,500 | 138,200 | 50,605 | 75,000 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christopher S. Boerner, PhD | Chief Executive Officer; Chairman | Executive Board | 2024 | 55 |
| David V. Elkins | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 57 |
| Hiroshi Chris Shibutani, M.D. | Executive Vice President; Chief Strategy Officer | Senior Management | 2025 | 62 |
| Amanda Poole | Chief People Officer; Executive Vice President | Senior Management | 2024 | 51 |
| Cristian Massacesi, M.D | Chief Medical Officer; Executive Vice President; Head - Development | Senior Management | 2025 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer